spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  nano-particle 

 HSMN NewsFeed - 18 Apr 2017
Matinas BioPharma Appoints Dominick DiPaolo as Senior Vice President of Quality and Regulatory Compliance
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Sep 2015
Matinas BioPharma Appoints Cochleate Technology Pioneer Raphael J. Mannino, Ph.D., as Senior Vice President and Chief Technology Officer
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 21 Jun 2010
Sosei to Acquire Activus Pharma
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 30 Jun 2008
Introgen Submits ADVEXIN(R) Regulatory Applications in the U.S. and Europe
Biopharmaceuticals Oncology FDA Regulatory
 HSMN NewsFeed - 28 May 2008
ADVEXIN(R) Improves Survival in Recurrent, Refractory Head and Neck Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Introgen Announces Positive Phase 2 Clinical Trial Results with INGN 225 Immunotherapy in Patients with Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2007
Introgen's ADVEXIN Demonstrates Clinical Benefit in Inherited Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Jan 2007
Introgen Reports that INGN 241 in Combination with Avastin(R) Results in Complete Tumor Regression
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
Introgen Announces New Clinical Data Confirming ADVEXIN(R) Survival Benefit
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Nov 2006
Introgen Obtains Exclusive License to Therapies Combining Epidermal Growth Factor Drugs and Tumor Suppressor Genes
Biopharmaceuticals Licensing Oncology
 HSMN NewsFeed - 31 Oct 2006
Introgen Therapeutics and Gendux AB Announce Agreement With European Medicines Agency to File for ADVEXIN Approval Under Exceptional Circumstance Rules
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Oct 2006
Introgen's ADVEXIN Molecular Targeted Therapy Is Active in Multiple Cancers; ADVEXIN Regulatory Program Advances
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2006
Introgen's ADVEXIN p53 Therapy Demonstrates Clinical Benefit in Inherited Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 May 2006
Introgen to Announce Important New Clinical Data for ADVEXIN Cancer Therapy at Major Medical Meetings
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 May 2006
Gendux AB and Introgen Therapeutics File European Orphan Drug Designation for ADVEXIN
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 May 2006
Introgen's ADVEXIN p53 Therapy Provided to Cancer Patients With Li-Fraumeni Syndrome
Biopharmaceuticals Oncology FDA
Return to NewsFeed  

 Additional items found! 13

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 13 additional stories matching:
nano-particle
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!